Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia cell proliferation and the mechanism of its antiproliferative effects. We found that EP leads to a decreased cell division rate, a block in G1 phase of cell cycle, and increased differentiation in human and murine leukemia cells. Because EP is species specific in that it can only bind TPO-R in human and primate cells, these findings further suggested that the antileukemic effect is independent of TPO-R. We found that treatment with EP leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner. Experimental increase of intracellular iron abrogated the antiproliferative and differentiation-inducing effects of EP, demonstrating that its antileukemic effects are mediated through modulation of intracellular iron content. Finally, determination of EP's antileukemic activity in vivo demonstrated its ability to prolong survival in 2 mouse models of leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Callens, C., Coulon, S., Naudin, J., Radford-Weiss, I., Boissel, N., Raffoux, E., Wang, P. H. M., Agarwal, S., Tamouza, H., Paubelle, E., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091488 · Cited by 197 · cited 2×
“Knowing that ROS levels vary with intracellular iron levels and that iron chelators have been shown to induce ROS formation, we investigated whether EP also induces ROS.(20) We used H2DCFDA (Invitrogen) with flow cytometry to assess intracellular ROS levels.”
Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184
Self-citationThe role of reactive oxygen and nitrogen species in cellular iron metabolism
MLADĚNKA, P., ŠIMŮNEK, T., HÜBL, M., & HRDINA, R. (2006) · Free Radical Research · doi:10.1080/10715760500511484 · Cited by 79
Cell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents
Pahl, P. M. B., & Horwitz, L. D. (2005) · Cancer Investigation · doi:10.1080/07357900500359976 · Cited by 40
Cited by
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Thrombopoietin receptor agonists: ten years later
Ghanima, W., Cooper, N., Rodeghiero, F., Godeau, B., & Bussel, J. B. (2019) · Haematologica · doi:10.3324/haematol.2018.212845 · Cited by 416
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor, U. C., Bartholdy, B., Cartier, J., Gao, E. N., Pietrak, B., Rendina, A. R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K. J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1930 · Cited by 180
Self-citation
Metadata
- Authors
- Roth, M., Will, B., Simkin, G., Narayanagari, S., Barreyro, L., Bartholdy, B., Tamari, R., Mitsiades, C. S., Verma, A., & Steidl, U.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-07-12
- Volume
- 120
- Issue
- 2
- Pages
- 386-394
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1998560266
- Cited by
- 164
- References
- 5
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. https://app.cochat.ai/papers/10.1182/blood-2011-12-399667
- The paper
- Roth, M., Will, B., Simkin, G., Narayanagari, S., Barreyro, L., Bartholdy, B., Tamari, R., Mitsiades, C. S., Verma, A., & Steidl, U. (2012). Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. https://doi.org/10.1182/blood-2011-12-399667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.